Investigational drug · Phase 3
Exa-cel
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sickle Cell Disease, Hematological Diseases, Hemoglobinopathies.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "Exa-cel"
First trial start
2018
Nov 27, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Exa-cel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sickle Cell Disease
- Hematological Diseases
- Hemoglobinopathies
Approved drugs for the same conditions: Sickle cell disease · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Exa-cel" as an intervention, largest first.
- A Long-term Follow-up Study in Participants Who Received CTX001Pivotal-lookingEnrolling by invitation
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04208529 · 160 participants (planned) · Start Jan 20, 2021 · Primary completion Sep 30, 2039
Drug: CTX001 · For: Beta-Thalassemia; Thalassemia; Sickle Cell Disease and 4 more
Sites: Palo Alto, California; Chicago, Illinois; New York, New York · 20 sites in all
- A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseasePivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03745287 · 63 participants · Start Nov 27, 2018 · Primary completion Jul 7, 2025
Drug: Exa-cel · For: Sickle Cell Disease; Hematological Diseases; Hemoglobinopathies
Sites: Palo Alto, California; Chicago, Illinois; New York, New York · 17 sites in all
- A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT03655678 · 59 participants · Start Sep 14, 2018 · Primary completion Nov 13, 2025
Drug: CTX001 · For: Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn and 2 more
Sites: Palo Alto, California; Chicago, Illinois; New York, New York · 14 sites in all
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseasePivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05477563 · 26 participants (planned) · Start Aug 2, 2022 · Primary completion Jun 9, 2027
Drug: CTX001 · For: Beta-Thalassemia; Thalassemia; Hematologic Diseases and 4 more
Sites: New York, New York; Charlotte, North Carolina; Nashville, Tennessee · 6 sites in all
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Pivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05356195 · 16 participants · Start May 3, 2022 · Primary completion Nov 14, 2027
Drug: CTX001 · For: Beta-Thalassemia; Thalassemia; Genetic Diseases, Inborn and 2 more
Sites: Nashville, Tennessee; Toronto, Canada; Düsseldorf, Germany · 6 sites in all
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Pivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05329649 · 13 participants · Start May 2, 2022 · Primary completion Jun 6, 2027
Drug: CTX001 · For: Sickle Cell Disease; Hydroxyurea Failure; Hydroxyurea Intolerance and 2 more
Sites: Charlotte, North Carolina; Philadelphia, Pennsylvania; Memphis, Tennessee · 7 sites in all
- Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/ βC GenotypePivotal-lookingWithdrawn
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05951205 · 0 participants · Start Jul 31, 2027 · Primary completion Dec 31, 2033
Drug: Exa-cel · For: Sickle Cell Disease
Newest research
PubMed records naming it or its code names, newest first.
- Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with transfusion-dependent β-thalassemia in the United States.
Udeze C, Gargano M, Yang H, et al. · J Med Econ 2026
- Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States.
Lopez A, Gargano M, Yang H, et al. · J Med Econ 2026
- Genotoxic safety and long-term engraftment dynamics of efficient translational CRISPR/Cas9 therapeutics for β-haemoglobinopathies from bench to clinical trials.
Al-Subaie AM, Borgio JF · Gene Ther 2026
- The expanding therapeutic landscape of β-thalassaemia.
Musallam KM, Sheth S, Locatelli F, et al. · Lancet Haematol 2026
- Efficacy, Safety, and Treatment-Delivery Feasibility of Autologous Gene Therapy for Sickle Cell Disease: A Systematic Review With Descriptive Synthesis of Clinical Trials.
Shaik MY, Divers S · Eur J Haematol 2026
- Recent trends and innovative strategies in the curative approach for β-thalassemia: a current prospect and future perspective.
Usmani F, Ali SU, Ahad F, et al. · Mol Biol Rep 2026
Also in development for Sickle Cell Disease
- FT-4202EtavopivatPhase 36 trials
Forma Therapeutics, Inc. · Sickle Cell Disease, Thalassemia
- IMR-687Tovinontrine, CRD-750Phase 23 trials
Cardurion Pharmaceuticals, Inc. · Heart Failure, Cardiovascular Diseases, Heart Diseases
- TebapivatAG-946Phase 22 trials
Agios Pharmaceuticals, Inc. · Myelodysplastic Syndromes, Sickle Cell Disease
- AnumigilimabPhase 21 trial
CSL Behring · Sickle Cell Disease
- BEAM-101Phase 21 trial
Beam Therapeutics Inc. · Sickle Cell Disease
- ITU512Phase 21 trial
Novartis · Sickle Cell Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.